Core Insights - Yield10 Bioscience, Inc. reported a net loss of $3.2 million for Q2 2024, an improvement from a net loss of $3.7 million in Q2 2023, indicating a reduction in losses per share from $15.42 to $5.04 [3] - The company is in the process of finalizing an asset purchase agreement with Nufarm, which includes an initial payment of $3 million and potential additional payments totaling $5 million for Omega-3 intellectual property [2][3] - Yield10 is leveraging advanced genetics to develop Camelina sativa as a platform crop for sustainable seed products, including oils for renewable diesel and omega-3 oils for various applications [4] Financial Performance - Yield10 reported a net loss of $3.2 million for the three months ended June 30, 2024, compared to a net loss of $3.7 million for the same period in 2023 [3] - Loss per share improved from $15.42 in Q2 2023 to $5.04 in Q2 2024, reflecting better financial management [3] Strategic Developments - The company is working closely with Nufarm to finalize an asset purchase agreement, which is expected to benefit shareholders and provide necessary cash flow [2] - A Memorandum of Understanding and License Agreement was signed with Nuseed Nutritional US Inc., granting Nufarm a commercial license for Omega-3 production, with potential payments of up to $5 million [2] - Yield10 and Nufarm have agreed to negotiate exclusively for the sale of substantially all of Yield10's remaining assets, pending shareholder approval [2] Company Overview - Yield10 Bioscience focuses on agricultural bioscience, utilizing advanced genetics to develop Camelina sativa for sustainable oil production [4] - The company is headquartered in Woburn, Massachusetts, with a subsidiary in Saskatoon, Canada [4]

- Nufarm to pay up to USD $5 million in consideration for the license -The parties will negotiate the sale of essentially all of Yield10's assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, INC. (State or other jurisdiction of incorporation or organization) 19 Presidential Way Woburn, MA 01801 (Addres ...

Financial Performance - Yield10 reported a net loss of $2.5 million for Q1 2024, or $4.77 per share, compared to a net loss of $3.8 million, or $18.16 per share, for Q1 2023[16] - Net loss for the three months ended March 31, 2024, was $2,472 million, an improvement from a net loss of $3,782 million in the same period of 2023[26] - Net cash used in operating activities decreased to $903 million from $2,667 million year-over-year[26] - Stock-based compensation expenses were $403 million, slightly down from $436 million in the prior year[26] Revenue and Cash Flow - Yield10 recognized $0.3 million in license revenue from the agreement with Vision Bioenergy Oilseeds during Q1 2024, with total revenue of $0.3 million compared to $0.06 million in Q1 2023[13][22] - Yield10 received $1 million in milestone payments from Vision Bioenergy Oilseeds in Q1 2024, contributing to its cash position[3][8] - The company anticipates total cash payments from Vision Bioenergy Oilseeds to reach $3 million, with $2 million received as of March 31, 2024[12] - Net cash provided by financing activities was $1,211 million, compared to $141 million in the previous year[26] Expenses and Liabilities - Research and development expenses decreased to $1.4 million in Q1 2024 from $2.2 million in Q1 2023, reflecting the company's efforts to align expenses with cash resources[15] - Total current liabilities increased to $6.21 million as of March 31, 2024, compared to $4.87 million as of December 31, 2023[24] - Deferred revenue increased significantly to $1,700 million, compared to no deferred revenue in the same period last year[26] - Accounts payable increased to $444 million from $307 million year-over-year[26] - The company reported a non-cash lease expense of $124 million, up from $104 million in the same period last year[26] Cash Position - The company ended Q1 2024 with $1.6 million in unrestricted cash, a net increase of $0.5 million from $1.1 million reported as of December 31, 2023[11] - Cash, cash equivalents, and restricted cash at the end of the period totaled $1,644 million, down from $2,073 million at the end of the same period in 2023[26] Regulatory and Development Updates - The U.S. EPA approved an amendment to the label language of INTERLINE Herbicide to include oilseed Camelina, allowing for better weed management during production[8] - Yield10 was granted a U.S. patent for oilseed plants engineered with a novel carbon fixation pathway in April 2024, expected to issue in the second half of 2024[4] - The company plans to plant its omega-3 DHA Camelina variety in fall 2024 as part of its seed scale-up program[8] Exchange Rate Impact - The effect of exchange rate changes on cash resulted in a positive impact of $4 million, compared to a negative impact of $3 million in the previous year[26] Capital Expenditures - The company had no purchases of property and equipment during the current period, compared to $9 million in the same period last year[26]

Yield10 Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Today April 01, 2024 Yield10 Bioscience, Inc. www.yield10bio.com NasdaqCM: YTEN "Sustainability is in Our Genes" Safe Harbor Statement 2 The statements made by Yield10 Bioscience, Inc. (the "Company," "we," "our" or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking st ...

Yield10 Bioscience, Inc. (OTCQB:YTEN) Q4 2023 Earnings Conference Call April 1, 2024 4:30 PM ET Company Participants Lynne Brum - Vice President of Planning and Corporate Communications Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President, Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Market Operator Welcome to the Fourth Quarter and Full Year 2023 Financial Results and Business Update ...

40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33133 YIELD10 BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware (State or other juri ...

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update "In early 2024, Yield10 granted to Vision Bioenergy Oilsee ...

Yield10 Bioscience, Inc. (OTCQB:YTEN) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Lynne Brum - Investor Relations Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President, Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Noel Parks - Tuohy Brothers Operator Hello and welcome to the Third Quarter 2023 Financial Results and Business Update Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, INC. (State or other jurisdiction of incorporation or organization) Indicate by check mark whether the regis ...